GNI Group Ltd.
TSE:2160.T
3,025 (JPY) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | GNI Group Ltd. |
Symbool | 2160.T |
Munteenheid | JPY |
Prijs | 3,025 |
Beurswaarde | 151,439,588,850 |
Dividendpercentage | 0% |
52-weken bereik | 1,537 - 3,865 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Ying Luo Ph.D. |
Website | https://www.gnipharma.com |
An error occurred while fetching data.
Over GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (JPY)
Cijfers zijn in miljoenen (JPY)